4//SEC Filing
Moxie Dwight 4
Accession 0001479290-24-000067
CIK 0001479290other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 6:44 PM ET
Size
7.3 KB
Accession
0001479290-24-000067
Insider Transaction Report
Form 4
Moxie Dwight
CLO & GC
Transactions
- Tax Payment
Common Stock
2024-03-15$5.30/sh−3,269$17,342→ 145,940 total - Sale
Common Stock
2024-03-18$5.04/sh−8,125$40,971→ 137,815 total
Footnotes (3)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 6,449 shares. The RSA vested in three equal annual installments from March 15, 2021.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F3]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001803375
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 6:44 PM ET
- Size
- 7.3 KB